The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANRO | +150.55% | N/A | N/A | -31% |
| S&P | +12.57% | +87.93% | +13.44% | +36% |
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 18.0% |
| Market Cap | $108.85M | -64.7% |
| Market Cap / Employee | $1.43M | 0.0% |
| Employees | 76 | 0.0% |
| Net Income | -$14.18M | 15.5% |
| EBITDA | -$14.79M | 20.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $137.82M | -24.2% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.40M | 110.5% |
| Short Term Debt | $1.12M | -73.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.77% | 0.0% |
| Return On Invested Capital | -45.46% | 2.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.92M | 22.1% |
| Operating Free Cash Flow | -$9.92M | 15.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.69 | 0.38 | 0.43 | 0.88 | -48.58% |
| Price to Tangible Book Value | 0.69 | 0.38 | 0.43 | 0.88 | -48.58% |
| Enterprise Value to EBITDA | 2.21 | 4.89 | 3.27 | 0.09 | -101.18% |
| Return on Equity | -154.0% | -38.0% | -42.8% | -45.0% | - |
| Total Debt | $16.94M | $26.44M | $27.31M | $27.52M | 63.96% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
